Premium
Cyclic Nucleotide Metabolism in Tumours
Author(s) -
Hunt N. H.,
Martin T. J.
Publication year - 1979
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1979.tb03401.x
Subject(s) - adenylate kinase , cyclic nucleotide , nucleotide , cell growth , cyclase , cell , metabolism , cyclic gmp , in vivo , receptor , function (biology) , hormone , signal transduction , mediator , cancer research , endocrinology , medicine , microbiology and biotechnology , biology , biochemistry , enzyme , genetics , gene
Summary: Many hormones act by combining with cell surface receptors and stimulating adenylate cyclase activity. The cyclic AMP generated is the mediator of a number of cellular metabolic processes. Other processes may be influenced by changes in cyclic GMP levels. Although much evidence from cultured cells suggested that low cellular levels of cyclic AMP and high levels of cyclic GMP are a feature of rapid cell growth and of malignant transformation, review of the data reveals many inconsistencies. Thus in established tumours growing in vivo, for example, cyclic AMP levels appear to be unrelated to tumour growth rates. It seems that tumour cell cyclic AMP is more likely concerned with the regulation of tumour cell function than of growth. This would have implications for therapy, in that drugs which influence cyclic nucleotide metabolism could influence tumour cell function. The control of cyclic nucleotide production in normal and tumour cells is discussed, together with the possible ways in which abnormalities of this may occur.